|Bid||0.5985 x 1100|
|Ask||0.6145 x 800|
|Day's Range||0.6000 - 0.6190|
|52 Week Range||0.5000 - 1.4000|
|Beta (3Y Monthly)||-0.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
If you're interested in iBio, Inc. (NYSEMKT:IBIO), then you might want to consider its beta (a measure of share price...
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”). Following iBio’s successful use of its technologies and manufacturing capabilities to advance the development of AzarGen’s surfactant protein therapeutic through an initial assessment of production feasibility, in May 2017, the two companies expanded their collaboration by initiating the development of a plant-made rituximab for the South African market under the MOU. Pursuant to the SOW1, iBio will manufacture research quantities of a plant-made rituximab for AzarGen using iBio’s proprietary FastPharming™ System.
NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product candidates for the territory of China. In addition, the Company will grant to CC-Pharming a research license to iBio’s FastPharming System and know-how for the evaluation of multiple product opportunities.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. iBio (NYSE: IBIO ) shares were down 14% to ...
NEW YORK, Aug. 19, 2019 -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a.
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...
Earlier in June, iBio introduced its new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors and other biologics. Focused initially on clients with preclinical and clinical stage programs, iBio’s fill-finish operation is housed in the Company’s 135,000 square foot CDMO facility located in Bryan, Texas. Pursuant to the supply agreement, iBio will formulate and fill clinical research quantities of one of the Customer’s investigational therapies into sterile vials for use in a planned late-stage clinical trial.
Robert Kay became the CEO of iBio, Inc. (NYSEMKT:IBIO) in 2008. First, this article will compare CEO compensation with...
NEW YORK, June 03, 2019 -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products,.
Every investor in iBio, Inc. (NYSEMKT:IBIO) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller comp...
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturer and product developer with proprietary, “green” technologies for biopharmaceutical production, today announced the appointment of Thomas F. Isett to its Board of Directors, effective immediately. Mr. Isett is an accomplished executive with decades of successful management and corporate development experience in the life sciences, with notable focus upon biologics contract development and manufacturing organizations (CDMOs). Advising, LLC, a management and strategy consulting firm, as well as Commence Bio, Inc., a private, early-stage developer of cellular immunotherapies. As Managing Director of i.e.
NEW YORK, Dec. 14, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, announced today that the Second Complaint it filed in iBio’s litigation against the Fraunhofer organization – this time against Fraunhofer Gesellschaft (“FhG”), complaining that FhG had committed fraud against and was responsible for contractual breaches against iBio – was dismissed by the Delaware Chancery Court as untimely filed. The original Complaint filed against Fraunhofer USA, Inc. (“FUSA”) on March 16, 2015, complained of breaches of contracts and misappropriation of iBio trade secrets and other intellectual property causing damages to iBio in excess of $100 million. The Chancery Court, sua sponte, initiated a partial Summary Judgment proceeding and determined that iBio exclusively owns all the technology FUSA developed or otherwise owned anytime before the end of 2014, and was required to transfer all such technology to iBio, but refused to do so. Proceedings under the original Complaint are continuing and are expected to lead to a trial date within the next 12-18 months. The dismissal of the Second Complaint against FhG has no effect on the action against FUSA.
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles, Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsored by Bio-Manguinhos/Fiocruz, a unit of the Brazilian Ministry of Health. “I am honored to have this opportunity to highlight the significant product flexibility, time- and cost-savings provided by iBio’s plant-based technology platform and CDMO offering to my fellow researchers and industry participants and, in so doing, help support the development of new business relationships and commercial collaborations for iBio in Brazil and internationally,” said Dr. Salgueiro.